NASDAQ:DCPH
Deciphera Pharmaceuticals Inc Stock News
$25.38
+0 (+0%)
At Close: May 03, 2024
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
12:24pm, Friday, 03'rd Dec 2021 Zacks Investment Research
The Zacks Analyst Blog Highlights: Vertex Pharma, Amgen, Blueprint Medicines, Deciphera Pharma and CTI BioPharma
Why Is Deciphera Pharmaceuticals, Inc. (DCPH) Down 78.5% Since Last Earnings Report?
04:31pm, Thursday, 02'nd Dec 2021 Zacks Investment Research
Deciphera Pharmaceuticals, Inc. (DCPH) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Biotech Stock Roundup: VRTX, AMGN's Pipeline Updates, BPMC's Acquisition & More
03:28pm, Thursday, 02'nd Dec 2021 Zacks Investment Research
Pipeline updates from Vertex (VRTX) and Amgen (AMGN) and other acquisition and regulatory updates have been the biotech sector's few key highlights during the past week.
Deciphera (DCPH) to Prioritize Key Pipeline Drugs, Cut Jobs
04:53pm, Wednesday, 01'st Dec 2021 Zacks Investment Research
Deciphera (DCPH) announces a corporate restructuring plan to prioritize development of vimseltinib and DCC-3116, streamline commercial operations and reduce workforce by almost 35%. Shares rise.
Why Deciphera Pharmaceuticals Shot 12% Higher Today
11:11pm, Tuesday, 30'th Nov 2021 The Motley Fool
The company announced a comprehensive restructuring program.
Deciphera Pharmaceuticals Is Trying to Beat Financial Cancer -- And Losing Hard
09:52pm, Tuesday, 30'th Nov 2021 InvestorPlace
Deciphera is a biotech full of hope but lagging on financial performance. The recent selloff in DCPH stock is justified by its poor trials.
Why Deciphera Pharmaceuticals Shot 12% Higher Today
06:11pm, Tuesday, 30'th Nov 2021
The company announced a comprehensive restructuring program.
Deciphera Pharmaceuticals Is Trying to Beat Financial Cancer — And Losing Hard
04:52pm, Tuesday, 30'th Nov 2021
Deciphera is a biotech full of hope but lagging on financial performance. The recent selloff in DCPH stock is justified by its poor trials.
Deciphera Pharma to undergo corporate restructuring; cuts workforce and ends program
02:27pm, Tuesday, 30'th Nov 2021 Seeking AlphaDeciphera Pharma Stock Rises After Announcing Corporate Restructuring
01:45pm, Tuesday, 30'th Nov 2021
Deciphera Pharmaceuticals Inc (NASDAQ: DCPH) will undergo a corporate restructuring to eliminate 35% of its workforce and end a Phase 1/2 program for solid tumors. Deciphera will implement an organ
Don't Bet on a Deciphera Stock Comeback
01:16pm, Tuesday, 30'th Nov 2021
Qinlock's potential is severely limited, and the rest of Deciphera's pipeline is far from the commercialization stage. With this, expect DCPH stock to remain a clear-cut "avoid" situation.
Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why
04:40pm, Monday, 29'th Nov 2021 Zacks Investment Research
Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.
Deciphera (DCPH) Down More Than 70% in Past 3 Months: Here's Why
01:05pm, Monday, 29'th Nov 2021
Deciphera's (DCPH) sole marketed drug, Qinlock, is approved for treating advanced gastrointestinal stromal tumors. The recent regulatory setback for Qinlock has hurt the stock.
Deciphera (DCPH) Gets EU Nod for Qinlock in Fourth-Line GIST
04:52pm, Tuesday, 23'rd Nov 2021 Zacks Investment Research
The European Commission approves Deciphera's (DCPH) Qinlock for the treatment of fourth-line gastrointestinal stromal tumor.
Here Are Reasons Why Deciphera Pharmaceuticals Inc. (NASDAQ: DCPH) Is A Great Choice Now
04:00pm, Tuesday, 23'rd Nov 2021 Stocks Register
The trading price of Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) closed higher on Monday, November 22, closing at $8.66, 1.88% higher than its previous close. >> 7 Top Picks for the Post-Pandemic Economy
